(Q43664148)

25 November 2017

Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making (English)

1 reference

25 November 2017

1 reference

Paul SR

1

1 reference

25 November 2017

Krauss GL

2

1 reference

25 November 2017

Miller NR

3

1 reference

25 November 2017

Medura MT

4

1 reference

25 November 2017

Miller TA

5

1 reference

25 November 2017

Johnson MA

6

1 reference

25 November 2017

1 April 2001

1 reference

25 November 2017

1 reference

25 November 2017

42

1 reference

25 November 2017

4

1 reference

25 November 2017

525-530

1 reference

Severe persistent visual field constriction associated with vigabatrin

25 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.49299.X

Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.49299.X

Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.49299.X

Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.49299.X

Visual function loss from vigabatrin: effect of stopping the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.49299.X

Visual field defects associated with vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.49299.X

10.1046/J.1528-1157.2001.49299.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference